

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

HEALTH TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Guidance development

MTA/STA Nivolumab with chemotherapy for neoadjuvant treatment of resectable non-small-cell lung cancer [ID3757]

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

Final Draft Guidance document

(when no draft guidance was issued)

- | |
|---|
| 1. Have the potential equality issues identified during the scoping process been addressed by the committee, and, if so, how? |
|---|

| |
|---|
| No equalities issues identified during the scoping process. |
|---|

- | |
|--|
| 2. Have any other potential equality issues been raised in the submissions, expert statements or academic report, and, if so, how has the committee addressed these? |
|--|

| |
|---|
| No other equality issues have been raised in the submissions. |
|---|

- | |
|--|
| 3. Have any other potential equality issues been identified by the committee, and, if so, how has the committee addressed these? |
|--|

| |
|---|
| No equality issues have been raised by the committee. |
|---|

- | |
|--|
| 4. Do the recommendations make it more difficult in practice for a specific group to access the technology compared with other groups? |
|--|

| |
|---|
| If so, what are the barriers to, or difficulties with, access for the specific group? |
| No |

| |
|---|
| 5. Is there potential for the recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability? |
| No |

| |
|---|
| 6. Are there any recommendations or explanations that the committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 4 or 5, or otherwise fulfil NICE's obligations to promote equality? |
| NA |

| |
|---|
| 7. Have the committee's considerations of equality issues been described in the final appraisal determination, and, if so, where? |
| No equality issues were identified that were not captured in the modelling (section 3.12 of final draft guidance document) |

Approved by Associate Director (name): ...Linda Landells.....

Date: 15 February 2022